Payment overview · 2025
General Payments
$342,537.12
189 reported records · 23 companies
Healthcare provider profile · identity verified
Eric D Donnenfeld, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology · GARDEN CITY, NY · NPI 1891790770
Verified facts
What the public records show
CMS Open Payments records show Eric D Donnenfeld, M.D. received $342,537.12 in general payments during 2025 across 189 reported records.
Tarsus Pharmaceuticals, Inc. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Miebo, Xdemvy, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYSUVIS as an associated drug or biological on 4201 records involving 2750 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eysuvis by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xiidra by this doctor in 2024.
Tarsus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XDEMVY as an associated drug or biological on 46638 records involving 15254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xdemvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138,837.44 | 40.5% | 33 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $82,572.79 | 24.1% | 58 | 2025 |
| Haag-Streit USA, Inc. | Unresolved — no canonical attribution shown | $60,000.00 | 17.5% | 1 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $13,687.71 | 4.0% | 9 | 2025 |
| Nordic Pharma, Inc. | Unresolved — no canonical attribution shown | $11,200.00 | 3.3% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $8,851.98 | 2.6% | 17 | 2025 |
| Alcon Research LLC | Unresolved — no canonical attribution shown | $8,500.00 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $7,315.40 | 2.1% | 9 | 2025 |
| Beaver-Visitec International, Inc. | Unresolved — no canonical attribution shown | $2,800.00 | 0.8% | 1 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $2,587.20 | 0.8% | 13 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $2,171.73 | 0.6% | 5 | 2025 |
| Carl Zeiss Meditec, Inc. | Unresolved — no canonical attribution shown | $1,312.50 | 0.4% | 2 | 2025 |
| TOPCON HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $1,250.00 | 0.4% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $250.12 | 0.1% | 8 | 2025 |
| LENSAR, Inc. | Unresolved — no canonical attribution shown | $244.04 | 0.1% | 1 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $221.96 | 0.1% | 6 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $197.91 | 0.1% | 9 | 2025 |
| Rayner Intraocular Lenses Limited | Unresolved — no canonical attribution shown | $188.85 | 0.1% | 2 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $185.86 | 0.1% | 4 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $71.96 | 0.0% | 4 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $40.25 | 0.0% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $30.04 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.38 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $245,632.00 | 38 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,000.00 | 1 |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,712.50 | 8 |
| Food and Beverage | $8,119.67 | 132 |
| Travel and Lodging | $3,023.95 | 9 |
| Grant | $49.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $29,453.91 | 23 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $29,436.82 | 23 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Research LLC, Alcon Vision LLC | $14,621.84 | 3 | 2025 |
Source payment records
|
|||||
| Compact Intuitiv Normalized: compact intuitiv |
Device | Johnson & Johnson Surgical Vision, Inc. | $13,175.00 | 7 | 2025 |
Source payment records
|
|||||
| IFS ADVANCED FEMTOSEC LASER Normalized: ifs advanced femtosec laser |
Device | Johnson & Johnson Surgical Vision, Inc. | $13,175.00 | 7 | 2025 |
Source payment records
|
|||||
| INTRALASE FS FEMTOSEC LASER Normalized: intralase fs femtosec laser |
Device | Johnson & Johnson Surgical Vision, Inc. | $13,175.00 | 7 | 2025 |
Source payment records
|
|||||
| LACRIFILL Normalized: lacrifill |
Device | Nordic Pharma, Inc. | $11,200.00 | 1 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $6,675.29 | 6 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $1,700.00 | 1 | 2025 |
Source payment records
|
|||||
| MEL 90 Normalized: mel 90 |
Device | Carl Zeiss Meditec, Inc. | $1,312.50 | 2 | 2025 |
Source payment records
|
|||||
| VisuMax Normalized: visumax |
Device | Carl Zeiss Meditec, Inc. | $1,312.50 | 2 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $1,200.00 | 1 | 2025 |
Source payment records
|
|||||
| IC-8 Apthera IOL Normalized: ic 8 apthera iol |
Device | Bausch & Lomb Americas Inc. | $933.40 | 3 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec, Inc. | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| CIRRUS HD-OCT Normalized: cirrus hd oct |
Device | Carl Zeiss Meditec, Inc. | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| IOLMaster 700 Normalized: iolmaster 700 |
Device | Carl Zeiss Meditec, Inc. | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $602.42 | 3 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $534.44 | 26 | 2025 |
Source payment records
|
|||||
| iStent Normalized: istent |
Device | Glaukos Corporation | $465.00 | 1 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $378.40 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $319.78 | 8 | 2025 |
Source payment records
|
|||||
| Clareon Normalized: clareon |
Device | Alcon Vision LLC | $295.62 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $250.12 | 8 | 2025 |
Source payment records
|
|||||
| LENSAR LASER SYSTEM Normalized: lensar laser system |
Device | LENSAR, Inc. | $244.04 | 1 | 2025 |
Source payment records
|
|||||
| Glaucoma Accessory Products Normalized: glaucoma accessory products |
Device | Glaukos Corporation | $238.15 | 1 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $221.96 | 6 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $197.91 | 9 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $185.86 | 4 | 2025 |
Source payment records
|
|||||
| iStent infinite Normalized: istent infinite |
Device | Glaukos Corporation | $181.41 | 1 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $169.81 | 3 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $134.31 | 1 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $124.64 | 1 | 2025 |
Source payment records
|
|||||
| Omidria Normalized: omidria |
Drug | Rayner Intraocular Lenses Limited | $114.36 | 1 | 2025 |
Source payment records
|
|||||
| RAYNER CATARACT SET 1 Normalized: rayner cataract set 1 |
Device | Rayner Intraocular Lenses Limited | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Aspheric Normalized: rayone aspheric |
Device | Rayner Intraocular Lenses Limited | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| RayOne EMV Normalized: rayone emv |
Device | Rayner Intraocular Lenses Limited | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Spheric Normalized: rayone spheric |
Device | Rayner Intraocular Lenses Limited | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| Simbrinza Normalized: simbrinza |
Drug | Alcon Vision LLC | $72.49 | 3 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $71.96 | 4 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $49.00 | 1 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MIEBO miebo |
2025 | Miebo | 2024 | 30 | exact normalized | Medicare Part D |
| XDEMVY xdemvy |
2025 | Xdemvy | 2024 | 44 | exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | EYSUVIS open payments reported associated product |
CMS Open Payments — General Payments 4201 supporting records · 2750 recipient NPIs · example record 1207357018 |
Eysuvis · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
30 | 19 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
110 | 73 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Tarsus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XDEMVY open payments reported associated product |
CMS Open Payments — General Payments 46638 supporting records · 15254 recipient NPIs · example record 1233825434 |
Xdemvy · 2024 Exact normalized brand match · 1 Part D row |
44 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 1159 | 631 |
| Ofloxacin | Ofloxacin | 1120 | 691 |
| Bromfenac Sodium | Bromfenac Sodium | 722 | 391 |
| Moxifloxacin | Moxifloxacin Hcl | 119 | 74 |
| Prolensa | Bromfenac Sodium | 110 | 73 |
| Loteprednol Etabonate | Loteprednol Etabonate | 70 | 47 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 68 | 65 |
| Latanoprost | Latanoprost | 62 | 29 |
| Restasis | Cyclosporine | 60 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 40 |
| Xdemvy | Lotilaner | 44 | 43 |
| Brimonidine Tartrate | Brimonidine Tartrate | 43 | 20 |
| Xiidra | Lifitegrast | 38 | 14 |
| Timolol Maleate | Timolol Maleate | 32 | 11 |
| Miebo | Perfluorohexyloctane/Pf | 30 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Difluprednate | Difluprednate | 22 | 16 |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 15 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Eysuvis | Loteprednol Etabonate | 19 | 15 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 11 |
| Lumigan | Bimatoprost | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 11 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342,537.12 · 189 records | Tarsus Pharmaceuticals, Inc. | CALLISTO eye, CATALYS SYSTEM, CIRRUS HD-OCT, Cequa, Clareon, Clareon PanOptix Pro, Compact Intuitiv, DEXTENZA, DURYSTA, Glaucoma Accessory Products, IC-8 Apthera IOL, IFS ADVANCED FEMTOSEC LASER, INTRALASE FS FEMTOSEC LASER, IOLMaster 700, KXL System, LACRIFILL, LENSAR LASER SYSTEM, LIGHT ADJUSTABLE LENS (LAL), MEL 90, MIEBO, OXERVATE, OZURDEX, Omidria, PURIFIED CORTROPHIN GEL, Photrexa Viscous and Photrexa, RAYNER CATARACT SET 1, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RayOne Aspheric, RayOne EMV, RayOne Spheric, Simbrinza, TECNIS IOL, TEPEZZA, TRYPTYR, VEVYE, VisuMax, XDEMVY, XEN GLAUCOMA TREATMENT SYSTEM, XIIDRA, enVista Envy IOL, enVista MX60 IOL, iDoseTR, iStent, iStent infinite | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Miebo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error